Literature DB >> 3903473

Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.

H Satoh, J R Gillette, H W Davies, R D Schulick, L R Pohl.   

Abstract

Four hours after the administration of halothane to phenobarbital-pretreated rats, subcellular fractions of liver were isolated and the proteins in the fractions were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to nitrocellulose sheets, and immunochemically stained with anti-trifluoroacetylated antibodies. The microsomal fraction contained the highest level of trifluoroacetylated adducts. Its major trifluoroacetylated component was immunochemically identified as a phenobarbital-inducible form of cytochrome P-450 (54 kDa), whereas the other observed trifluoroacetylated protein fraction (59 kDa) was not identified. The plasma membrane fraction also contained a 54-kDa trifluoroacetylated adduct, which was immunochemically related to the 54-kDa cytochrome P-450. Microsomes from untreated rats that were administered halothane contained only the 59-kDa trifluoroacetylated protein fraction. The specificity of the immunochemical staining for the bound oxidative metabolite of halothane was confirmed by the finding that rats treated with deuterated halothane had considerably less stained liver proteins than did those treated with halothane. These results suggest that the CF3COX oxidative metabolite of halothane is so reactive that it binds predominantly to the cytochrome P-450 that produced it.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903473

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

Review 1.  Protein damage by reactive electrophiles: targets and consequences.

Authors:  Daniel C Liebler
Journal:  Chem Res Toxicol       Date:  2007-12-04       Impact factor: 3.739

Review 2.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

3.  Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.

Authors:  H Satoh; B M Martin; A H Schulick; D D Christ; J G Kenna; L R Pohl
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 4.  Mechanisms of unpredictable adverse drug reactions.

Authors:  M J Rieder
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

Review 5.  Drug-induced immunotoxicity.

Authors:  P M Dansette; E Bonierbale; C Minoletti; P H Beaune; D Pessayre; D Mansuy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.441

6.  Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis.

Authors:  M Bourdi; D Larrey; J Nataf; J Bernuau; D Pessayre; M Iwasaki; F P Guengerich; P H Beaune
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Protein targets of reactive electrophiles in human liver microsomes.

Authors:  Nah-Young Shin; Qinfeng Liu; Sheryl L Stamer; Daniel C Liebler
Journal:  Chem Res Toxicol       Date:  2007-05-05       Impact factor: 3.739

8.  Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug.

Authors:  P Beaune; P M Dansette; D Mansuy; L Kiffel; M Finck; C Amar; J P Leroux; J C Homberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

9.  Localization of halothane-induced antigen in situ by specific anti-halothane metabolite antibodies.

Authors:  A K Hubbard; T P Roth; S Schuman; A J Gandolfi
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

10.  Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis.

Authors:  Peiman Habibollahi; Nastaran Mahboobi; Sara Esmaeili; Saeid Safari; Ali Dabbagh; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.